Curaleaf Holdings (CURLF) Asset Writedowns and Impairment (2021 - 2025)
Curaleaf Holdings (CURLF) posted quarterly Asset Writedowns and Impairment of $4.3 million for Q4 2025, up 481.84% year-on-year from $740922.4 in Q4 2024, and up 608.37% on a QoQ basis from -$848000.0 in Q3 2025.
Curaleaf Holdings (CURLF) Asset Writedowns and Impairment (2021 - 2025) Analysis & Trends
Curaleaf Holdings (CURLF) has reported Asset Writedowns and Impairment for 5 consecutive years, with $4.3 million the latest figure, recorded in Q4 2025.
- Quarterly Asset Writedowns and Impairment rose 481.84% year-over-year to $4.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.7 million (down 58.98% YoY) and the FY2025 annual result came in at $977000.0, up 135.99% from the prior year.
- Asset Writedowns and Impairment climbed to $4.3 million in Q4 2025 per CURLF's latest filing, from -$848000.0 in the prior quarter.
- Over the last five years, Asset Writedowns and Impairment for CURLF reached as high as $116.9 million in Q4 2022 and fell as low as -$1.1 million in Q4 2024.
- A 5-year average of $16.7 million and a median of $2.0 million in 2023 frame the typical range for Asset Writedowns and Impairment.
- Annual changes were most pronounced in 2022 — Asset Writedowns and Impairment jumped 1170.42% — and 2024, when it slumped 118.22%.
- Year by year, Asset Writedowns and Impairment stood at $9.2 million in 2021, then soared by 1170.42% to $116.9 million in 2022, then tumbled by 94.7% to $6.2 million in 2023, then slumped by 118.22% to -$1.1 million in 2024, then surged by 481.84% to $4.3 million in 2025.
- According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $4.3 million, -$848000.0, and -$1.1 million for Q4 2025, Q3 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.51 Bn | 87.64 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.95 Bn | 32.21 Bn | 1.97 Bn |
| 3 | Zoetis | 32.59 Bn | 30.65 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.51 Bn | 23.45 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.06 Bn | 20.91 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - |
| 7 | Viatris | 20.25 Bn | 18.44 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.48 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Curaleaf Holdings | 6.98 Bn | 6.98 Bn | 157.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.31 Mn |
| Dec 31, 2025 | 4.31 Mn |
| Sep 30, 2025 | -848,000.00 |
| Sep 30, 2025 | -848,000.00 |
| Dec 31, 2024 | -1.13 Mn |
| Dec 31, 2024 | -1.13 Mn |
| Sep 30, 2024 | -642,000.00 |
| Sep 30, 2024 | -642,000.00 |
| Dec 31, 2023 | 6.20 Mn |
| Dec 31, 2023 | 6.20 Mn |
| Sep 30, 2023 | -301,000.00 |
| Sep 30, 2023 | -301,000.00 |
| Dec 31, 2022 | 116.88 Mn |
| Dec 31, 2022 | 116.88 Mn |
| Dec 31, 2021 | 9.20 Mn |
| Dec 31, 2021 | 9.20 Mn |